ClinicalTrials.gg
Active, not recruitingNCT04055493ADAPTcycleUpdated Oct 9, 2026

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

A Phase 3 interventional study of Ribociclib 200Mg Oral Tablet in Breast Cancer Female, sponsored by Women's Cancer Study Group GmbH. Active, not recruiting at 86 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Women's Cancer Study Group GmbH · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 9, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,684
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing ribociclib in Breast Neoplasms — 17 open to participants now, 31 under way, 8 of them phase 3. ribociclib · Breast Neoplasms.

Enrollment
3rd of 70
1,684 · median 116
Started
2019
with 5 others
Phase 3
19 of 70
4 open now
Primary completion
2027-07
later than 14 of 30 live
Registered
38th of 70
by date

Among the 70 studies testing ribociclib in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 6 that started in 2019, is one of 19 in phase 3, reaches primary completion later than 14 of the 30 other live ones, and was the 38th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 70 studies testing ribociclib in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About ribociclib

ribociclib: first FDA approval 2017 (KISQALI), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing ribociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The study investigates, whether the patient group with intermediate-risk early breast cancer benefits from treatment with ribociclib in combination with endocrine therapy compared to standard-of-care chemotherapy (followed by adjuvant endocrine therapy).

Read the detailed description

The WSG ADAPT trial program is one of the first new generation trials addressing the issue of individualization of (neo)-adjuvant decision-making in early breast cancer (EBC) in a subtype-specific manner. The first WSG ADAPT umbrella trial (NCT01779206) aimed to establish early predictive molecular surrogate markers for response after a short 3-week induction treatment.

The goals of the WSG ADAPT trial program - early response assessment and subtype-specific therapy tailoring to those patients who are most likely to benefit - have contributed to the very positive national and international feedback to the ADAPT concept as a whole.

The aim of this ADAPTcycle phase-III-trial is to investigate whether the intermediate-risk patient group identified during the screening phase derives additional benefit from treatment with ribociclib in combination with ET compared to chemotherapy (followed by adjuvant ET).

03

Conditions studied

  • Breast Cancer Female

Browse trials for

Keywords

  • early breast cancer
  • ADAPT
  • endocrine therapy
  • ribociclib
  • intermediate risk
  • HER2 negative
  • HR positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in this study have to meet all of the following criteria:

A. Prior to REGISTRATION in the study:

1. Written prior to any screening procedures. 2. Female. 3. ≥ 18 years of age. 4a. EITHER: (Post)menopausal status at the time of initiation of (neo)adjuvant study medication

  • patient underwent bilateral oophorectomy, or
  • age ≥ 60, or
  • age \< 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) and/or FSH and estradiol in the range per local normal range.

    4b. OR: Pre-menopausal patients:

  • confirmed negative serum pregnancy test (β-hCG) before starting study treatment, or
  • patient has had a hysterectomy. 5. confirmed diagnosis of primary estrogen-receptor positive and/or progesterone-receptor positive (> 1%) early breast cancer by local laboratory.

    6. Patient has -negative breast cancer defined as

  • a negative in-situ hybridization test or an IHC status of 0, 1+, or 2+,
  • if IHC is 2+, a negative in-situ hybridization (FISH, CISH, or SISH) test is required (based on the most recently analyzed tissue sample and all tested by a local laboratory).

    7. Local therapy of breast cancer (if treatment or planned if neoadjuvant treatment) according to current guidelines.

Note: This may include radiotherapy of breast cancer.

B. Prior to RANDOMIZATION in the study 8. No evidence of distant (confirmed prior to randomization by, preferentially, CT thorax / abdomen, X-ray chest, ultrasound liver, bone scan, or PET-CT).

9. Patient has available tumor tissue from diagnostic . 10. Patient is classified as intermediate risk according to the ADAPT intermediate-risk definition (i) (as follows), or (only in case of missing Oncotype DX or Ki-67 response data), according to the clinical intermediate-risk definition (ii) (as follows).

(i). ADAPT intermediate-risk definition: Patient meets one of the following criteria:

  • c/pN0, RS ≤ 25 with luminal-B-like (Ki-67 ≥20% or G3) or c/pT2-4 without endocrine response (post-endocrine Ki-67 > 10 %)
  • c/pN1, RS ≤ 25 without endocrine response (post-endocrine Ki-67 > 10 %)
  • c/pN0, RS > 25 with luminal-B-like (Ki-67 ≥20% or G3) or c/pT2-4 with endocrine response (Ki-67 ≤ 10 %)
  • c/pN1, RS > 25 with endocrine response (Ki-67 ≤ 10 %)
  • c/pN2-3, RS ≤ 25 with endocrine response (Ki-67 ≤ 10 %). Note: Postmenopausal patients with pT1-2/pN0 disease and RS \< 25, as well as premenopausal patients with pT1-2/pN0 disease and RS\<16, are recommended to be treated by endocrine therapy alone and not to be randomized (at investigator´s discretion).

(ii). Clinical intermediate-risk definition (ascertained by investigator): Clinical intermediate risk may be ascertained by the investigator prior to randomization if at maximum two of the following three risk factors are present (according to primary diagnosis / 1st sample):

  1. cT2-4
  2. c/pN positive
  3. G3 and / or Ki-67 ≥ 20% Note: Inclusion of a patient according to "clinical intermediate risk" is permitted only in case of missing baseline Oncotype DX® or Ki-67 decrease. In this case, investigators will follow a risk-based, step-wise assessment process.

11. No for (neo)-adjuvant ET. 12. (ECOG) performance status 0 or 1. 13. Patient has adequate bone marrow and organ function as defined by the following laboratory values:

  • ≥ 1.5 × 109/L,
  • ≥ 100 × 109/L,
  • ≥ 9.0 g/dL,
  • estimated (eGFR) ≥ 30 mL/min by a formula,
  • ≤ 1.5,
  • serum creatinine \< 1.5 mg/dL,
  • total \< , except for patients with Gilbert's Syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN,
  • (AST) \< 2.5 × ULN,
  • alanine transaminase (ALT) \< 2.5 × ULN. 14. 2-lead- (CANKADO) with:
  • interval at screening \< 450 msec (using Fridericia's correction),
  • mean resting heart rate 50-90 bpm (determined from the ECG). 15. Ability to swallow ribociclib tablets or to administer other study medication, respectively.

    16. Ability to communicate with the investigator and comply with study procedures.

    17. Willing to remain during therapy at the clinical site, as required by the protocol.

Exclusion criteria

Exclusion Criteria:

Patients eligible for inclusion in this study must not meet any of the following criteria:

  1. Patient with distant of breast cancer beyond regional lymph nodes.
  2. Patient has received prior (neo)- treatment with chemotherapy, ET, or any CDK4/6 inhibitor for breast cancer.
  3. Patient has received tamoxifen, raloxifene, or aromatase inhibitors (AIs) for reduction in risk ("chemoprevention") of breast cancer and/or treatment for osteoporosis within last 2 years prior to screening.
  4. Patient has received prior neoadjuvant/adjuvant treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin or 900 mg/m² or more for epirubicin.
  5. Patient with a known to any of the of ribociclib, ET, or standard-of-care chemotherapy.
  6. Patient with inflammatory breast cancer at screening.
  7. Patient is concurrently using other anti-cancer therapy.
  8. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
  9. Patient is currently receiving warfarin or other coumarin-derived anti-coagulant for treatment, prophylaxis, or otherwise.
  10. Patient has not recovered from clinical and laboratory acute toxicities related to prior anticancer therapies to version 5.0 Grade ≤ 1.
  11. Patient has a concurrent , or malignancy within 5 years of randomization, or known history of invasive breast cancer.
  12. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small-bowel resection).
  13. Patient has a known history of infection.
  14. Patient has known active hepatitis-B-virus () or hepatitis-C-virus () infection.
  15. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator´s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study, or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial, or viral infections, etc.).
  16. , uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following:

    • history of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to study entry,
    • documented cardiomyopathy,
    • (LVEF) \< 50 % as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO),
    • long syndrome, family history of idiopathic sudden death, congenital long QT syndrome, or any of the following:

      • risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/ symptomatic bradycardia,
      • concomitant medications with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued or replaced by safe alternative medication (e.g., within 5 half-lives or 7 days prior to starting study drug),
      • inability to determine the QTcF interval,
      • clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left-bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II, and 3rd-degree AV block),
      • systolic blood pressure (SBP) > 160 or \< 90 mmHg.
  17. Patient is currently receiving any of the following substances, which cannot be discontinued 7 days prior to Cycle 1 Day 1:

    • concomitant medications, herbal supplements, fruits (e.g. grapefruit, pomegranates, pomelos, star fruit, Seville oranges) and their juices that are strong inducers or inhibitors of /5,
    • medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
  18. Patient is currently receiving or has received systemic ≤ 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment.
  19. Participation in a prior study within 30 days prior to enrollment or within five half-lives of the investigational product, whichever is longer.
  20. Not able to understand and to comply with study instructions and requirements.
  21. Pregnant or nursing (lactating) woman.
  22. Woman of defined as woman physiologically capable of becoming pregnant, unless she is using highly effective methods of during the study treatment and for 21 days after stopping the treatment:

    • total abstinence (when this is in line with the preferred and usual lifestyle of the patient).
    • female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment.
    • male partner sterilization (at least 6 months prior to study screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient.
    • placement of an intrauterine device (IUD).
  23. Use of oral (estrogen and progesterone), transdermal, injected, or implanted hormonal methods of contraception as well as hormonal replacement therapy.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,684 participants (actual)

Study arms

  • Experimental
    Ribociclib plus ET

    Ribociclib 600mg / day over 26 cycles + endocrine treatment of physician´s choice

    Drug: Ribociclib 200Mg Oral Tablet

  • No intervention
    Standard-of-care chemotherapy

    Standard-of-care chemotherapy according to the clinical guidelines, e.g., of the Breast Committee of the German Gynecological Oncology Group (AGO), and regional prescribing information depending on patient's needs for 16-24 weeks,

Interventions

06

What researchers measure

Primary outcomes

  1. invasive disease-free survival (iDFS)

    superiority in invasive disease-free survival (iDFS) of ribociclib + ET vs. standard-of-care chemotherapy

    Time frame: at end of study, on average 5 years after start of treatment

  2. distant disease-free survival (dDFS)

    distant disease-free survival (dDFS) in the ribociclib + ET-group to demonstrate survival rate \>92%

    Time frame: at end of study, on average 5 years after start of treatment

Secondary outcomes

  1. overall survival (OS) 95 % CI

    95 %-confidence interval (CI) for OS in both arms

    Time frame: at end of study, on average 5 years after start of treatment

  2. distant disease-free survival (dDFS) 95 % CI

    95 %-confidence interval (CI) for dDFS in both arms

    Time frame: at end of study, on average 5 years after start of treatment

  3. QoL

    quality of life (QoL) and correlation to treatment-related symptoms measured by EQ-VAS and triggered symptom questionnaire,

    Time frame: at end of study, on average 5 years after start of treatment

  4. treatment adherence

    treatment adherence measured by drug intake compared between treatment arms

    Time frame: at end of study, on average 5 years after start of treatment

  5. pathological complete response (pCR)

    Pathological response rate (defined as ypT0/is/ypN0), as well as further definitions (ypT0/ypN0; ypT0/is/any ypN, near pCR (ypT1a/any ypN)), in neoadjuvant treated patients

    Time frame: at end of study, on average 5 years after start of treatment

  6. clinical response rate

    clinical response rate (by palpation, ultrasound, and further methods) compared between treatment arms

    Time frame: at end of study, on average 5 years after start of treatment

  7. rate of breast-conservation therapy

    prevalence of breast conservation therapy vs. mastectomy compared between treatment arms

    Time frame: at end of study, on average 5 years after start of treatment

07

Study locations

86 sites
  • Ost-Alb Klinikum Brustzentrum
    Aalen, Baden-Wurttemberg 73430, Germany
  • Stadtklinik Baden-Baden Brustzentrum
    Baden-Baden, Baden-Wurttemberg 76532, Germany
  • Kreiskliniken Böblingen Klinikum Böblingen Frauenklinik
    Böblingen, Baden-Wurttemberg 71032, Germany
  • Uniklinikum Freiburg Frauenklinik
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Praxis für interdisziplinäre Onkologie & Hämatologie GbR Praxis am Diakonieklinikum
    Freiburg im Breisgau, Baden-Wurttemberg 79110, Germany
  • SLK-Kliniken-Heilbronn Frauenklinik
    Heilbronn, Baden-Wurttemberg 74078, Germany
  • Klinikum Ludwigsburg Klinik für Frauenheilkunde u. Geburtshilfe
    Ludwigsburg, Baden-Wurttemberg 71640, Germany
  • Universitätsklinikum Tübingen Universitäts-Frauenklinik
    Tübingen, Baden-Wurttemberg 72016, Germany
  • Universitätsfrauenklinik Ulm Frauenheilkunde und Geburtshilfe
    Ulm, Baden-Wurttemberg 89075, Germany
  • GRN Klinik Weinheim Gynäkologie
    Weinheim, Baden-Wurttemberg 69469, Germany
  • Klinikum der Universität München Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum
    Munich, Bavaria 80337, Germany
  • Rotkreuzkliniken München Frauenklinik - Gynäkologie
    München, Bavaria 80637, Germany
  • Frauenklinik und Poliklinik / Studienzentrale Josef-Schneider-Straße 4
    Würzburg, Bavaria 97080, Germany
  • Carl-Thiem-Klinikum / Brustzentrum Senologie der Frauenklinik
    Cottbus, Brandenburg 03048, Germany
  • Schwerpunktpraxis Gynäkologische Onkologie Praxis Dr. Heinrich
    Fürstenwalde, Brandenburg 15517, Germany
  • Klinikum Ernst von Bergmann Klinik für Gynäkologie und Geburtshilfe
    Potsdam, Brandenburg 14467, Germany
  • UKE Hamburg / Frauenklinik Brustzentrum am UKE
    Hamburg, Free and Hanseatic City of Hamburg 20246, Germany
  • Agaplesion Diakonieklinikum Hamburg Frauenklinik, Brustzentrum u. Gyn. Tumorzentrum / Gyn. Studienambulanz
    Hamburg, Free and Hanseatic City of Hamburg 20259, Germany
  • Mammazentrum Hamburg am Krankenhaus Jerusalem
    Hamburg, Free and Hanseatic City of Hamburg 20357, Germany
  • Hämatologisch/Onkologische Schwerpunktpraxis Praxis Dr. Schreiber
    Bremen, Free Hanseatic City of Bremen 28209, Germany
  • Klinikum Bremerhaven Reinkenheide Frauenklinik
    Bremerhaven, Free Hanseatic City of Bremen 27574, Germany
  • AGAPLESION Markus Krankenhaus / Brustzentrum Gynäkologie und Geburtshilfe
    Frankfurt am Main, Hesse 60431, Germany
  • Klinikum Frankfurt Höchst Klinik für Gynäkologie und Geburtshilfe
    Frankfurt am Main, Hesse 65929, Germany
  • Klinikum Kassel Frauenklinik
    Kassel, Hesse 34125, Germany
  • Sana Klinikum Klinik für Gynäkologie und Geburtshilfe, Studienambulanz AOZ
    Offenbach, Hesse 63069, Germany
  • St. Josefs-Hospital Wiesbaden Frauenklinik - Gynäkologie
    Wiesbaden, Hesse 65189, Germany
  • Frauenärzte Casparistraße Studien GbR BS
    Braunschweig, Lower Saxony 38100, Germany
  • MVZ II der Niels Stensen Kliniken Onkologie u. Hämatologie, Brustzenzrum
    Georgsmarienhütte, Lower Saxony 49124, Germany
  • Medizinische Hochschulle Hannover Klinik für Frauenheilkunde und Geburtshilfe
    Hanover, Lower Saxony 30539, Germany
  • DIAKOVERE Henriettenstift Frauenklinik
    Hanover, Lower Saxony 30559, Germany
  • Gynäkologische Gemeinschaftspraxis-Ärztehaus am Bahnhofsplatz Klinische Studien
    Hildesheim, Lower Saxony 31134, Germany
  • Städtisches Klinikum Lüneburg Frauenklinik
    Lüneburg, Lower Saxony 21339, Germany
  • MVZ Klinik Dr. Hancken Haematologie/Onkologie
    Stade, Lower Saxony 21680, Germany
  • UFK Klinikum Südstadt Frauenklinik
    Rostock, Mecklenburg-Vorpommern 18059, Germany
  • Marienhospital Studienzentrale BrustCentrum Aachen-Kreis Heinsberg
    Aachen, North Rhine-Westphalia 52066, Germany
  • Universitätsklinikum Aachen, Frauenklinik - Senologie
    Aachen, North Rhine-Westphalia 52074, Germany
  • EVK Bergisch Gladbach Brustzentrum
    Bergisch Gladbach, North Rhine-Westphalia 51465, Germany
  • Onkologische Schwerpunktpraxis Bielefeld Praxis Dr. Just
    Bielefeld, North Rhine-Westphalia 33604, Germany
  • Marienhospital Bottrop Klinik für Gynäkologie und Geburtshilfe / Gyn-Ambulanz
    Bottrop, North Rhine-Westphalia 46236, Germany
  • St. Elisabeth-Krankenhaus Hohenlind Brustzentrum
    Cologne, North Rhine-Westphalia 50935, Germany
  • Uniklinik Köln / Gebäude 70 Studienzentrale der Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
    Cologne, North Rhine-Westphalia 50937, Germany
  • Kliniken der Stadt Köln / Krankenhaus Holweide Brustzentrum Holweide
    Cologne, North Rhine-Westphalia 51067, Germany
  • Klinikum Dortmund gGmbH Frauenklinik
    Dortmund, North Rhine-Westphalia 44137, Germany
  • Universitätsklinikum Düsseldorf Klinik für Frauenheilkunde & Geburtshilfe
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Luisenkrankenhaus GmbH GynOnco Düsseldorf
    Düsseldorf, North Rhine-Westphalia 40235, Germany
  • Praxis Dr. Adhami
    Erkelenz, North Rhine-Westphalia 41812, Germany
  • St. Antonius Hospital Klinik für Hämatologie/Onkologie
    Eschweiler, North Rhine-Westphalia 52249, Germany
  • Universitätsklinikum Essen Klinik für Frauenheilkunde und Geburtshilfe
    Essen, North Rhine-Westphalia 45130, Germany
  • Kliniken Essen-Mitte, Klinik für Senologie/Interdisziplinäres Brustzentrum
    Essen, North Rhine-Westphalia 45136, Germany
  • Evangelische Kliniken Gelsenkirchen GmbH Klinik für Senologie
    Gelsenkirchen, North Rhine-Westphalia 45879, Germany
  • Wilhelm-Anton-Hospital Goch Klinik für Innere Medizin, Hämatologie u. Onkologie
    Goch, North Rhine-Westphalia 47574, Germany
  • Onkodok GmbH
    Gütersloh, North Rhine-Westphalia 33332, Germany
  • St. Barbara Klinik Brustzentrum
    Hamm, North Rhine-Westphalia 59073, Germany
  • Klinikum Leverkusen Medizinische Klinik 3
    Leverkusen, North Rhine-Westphalia 51375, Germany
  • Praxis für gynäkologische Onkologie am Ev. Krankenhaus Bethesda
    Mönchengladbach, North Rhine-Westphalia 41061, Germany
  • St. Franziskus-Hospital Brustzentrum
    Münster, North Rhine-Westphalia 48145, Germany
  • Universitätsklinikum Frauenheilkunde
    Münster, North Rhine-Westphalia 48149, Germany
  • ONCOLOGIANOVA Praxis Dr. Emde
    Recklinghausen, North Rhine-Westphalia 45659, Germany
  • Marienkrankenhaus Schwerte Brustzentrum
    Schwerte, North Rhine-Westphalia 58239, Germany
  • Marien-Krankenhaus Klinik für Gynäkologie und Geburtshilfe
    Siegen, North Rhine-Westphalia 57072, Germany
  • Diakonie Klinikum Jung Stilling Brustzentrum
    Siegen, North Rhine-Westphalia 57074, Germany
  • Praxisnetz Hämatologie / internistische Onkologie Praxis Troisdorf
    Troisdorf, North Rhine-Westphalia 53840, Germany
  • Christliches Klinikum Unna gGmbH Brustzentrum
    Unna, North Rhine-Westphalia 59423, Germany
  • Praxis für Hämatologie und internistische Onkologie Praxis Dr. Nusch
    Velbert, North Rhine-Westphalia 42551, Germany
  • Marien Hospital / Senologie Brustzentrum
    Witten, North Rhine-Westphalia 58452, Germany
  • Helios Universitätsklinikum Frauenheilkunde & Geburtshilfe
    Wuppertal, North Rhine-Westphalia 42283, Germany
  • Katholisches Klinikum Koblenz-Montabaur-Marienhof Koblenz Marienhof Koblenz - Gynäkologie
    Koblenz, Rhineland-Palatinate 56073, Germany
  • Klinikum Mutterhaus der Borromäerinnen Innere Medizin I / Onkologie
    Trier, Rhineland-Palatinate 54290, Germany
  • Universitätsklinikum des Saarlandes Frauenklinik
    Homburg, Saarland 66421, Germany
  • DRK Kliniken Saar / Krankenhaus Saarlouis Brustzentrum
    Saarlouis, Saarland 66740, Germany
  • Klinikum Chemnitz Frauenklinik / Brustzentrum
    Chemnitz, Saxony 09116, Germany
  • Universitätsklinikum Dresden Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
    Dresden, Saxony 01307, Germany
  • Universitätsklinikum Leipzig Gynäkologie und Universitäres Krebszentrum; Klinik und Poliklinik für Frauenheilkunde
    Leipzig, Saxony 04015, Germany
  • Kliniken St. Georg Klinik für Gynäkologie und Geburtshilfe
    Leipzig, Saxony 04129, Germany
  • Klinikum Obergöltzsch-Rodewisch Frauenklinik
    Rodewisch, Saxony 08228, Germany
  • Universitätsklinikum Halle Universitätsklinik für Gynäkologie
    Halle, Saxony-Anhalt 06120, Germany
  • Altmark-Klinikum Salzwedel Klinik für Frauenheilkunde
    Hansestadt Salzwedel, Saxony-Anhalt 29410, Germany
  • Johanniter Frauenklinik Stendal Gynäkologie
    Stendal, Saxony-Anhalt 39576, Germany
  • Universitätsklinikum Schleswig-Holstein Campus Lübeck, Frauenklinik
    Lübeck, Schleswig-Holstein 23538, Germany
  • Charité Berlin, Klinik für Gynäkologie m.S. Senologie Brustzentrum (CCM)
    Berlin, State of Berlin 10117, Germany
  • St. Gertrauden Krankenhaus Brustzentrum City Berlin
    Berlin, State of Berlin 10713, Germany
  • Vivantes Klinikum Am Urban Brustzentrum
    Berlin, State of Berlin 10967, Germany
  • DRK Klinikum Berlin-Köpenick Brustzentrum
    Berlin, State of Berlin 12559, Germany
  • Evangelisches Waldkrankenhaus Spandau Klinik für Gynäkologie und Geburtshilfe
    Berlin, State of Berlin 13589, Germany
  • Universitätsklinikum Jena Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin
    Jena, Thuringia 07747, Germany
  • MVZ Nordhausen Praxis Dr. Andrea Grafe
    Nordhausen, Thuringia 99734, Germany
08

References and documents

Publications

  • Klier K, Patel YJ, Schinkothe T, Harbeck N, Schmidt A. Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study. JMIR Cardio. 2023 Sep 11;7:e48096. doi: 10.2196/48096. PubMed 37695655 ↗

Individual participant data

Plan to share: Yes — The sponsor is committed to following high ethical standards for reporting study results, including the timely communication and publication of clinical trial results, whatever their outcome. The sponsor assures that the key design elements of this protocol will be posted on a publicly accessible database, e.g., www.clinicaltrials.gov, before study start. As part of its commitment to full transparency in publications, the sponsor supports the full disclosure of all funding sources for the study and publications, as well as any actual and potential conflicts of interest of financial and non-financial nature by all authors, including medical writing / editorial support, if applicable.

Supporting information: Clinical study report

Time frame: Within 1 year after end of study.

Access criteria: for regulatory use only

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Jul 2027, 96 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 96 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2019
First posted
Aug 13, 2019
StartActual
Jul 2, 2019
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
West German Study Group→Women's Cancer Study Group GmbH
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Sponsor West German Study Group→Women's Cancer Study Group GmbH
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04055493
Lead sponsor
Women's Cancer Study Group GmbH
Responsible party
Sponsor
First posted
Aug 13, 2019
Start date
Jul 2, 2019
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Nadia Harbeck, Prof. Dr.
principal investigator · Ludwigs-Maximilians-University Munich, Breast Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribociclib

Start the discussion